214 related articles for article (PubMed ID: 18723476)
1. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
Tijink BM; Laeremans T; Budde M; Stigter-van Walsum M; Dreier T; de Haard HJ; Leemans CR; van Dongen GA
Mol Cancer Ther; 2008 Aug; 7(8):2288-97. PubMed ID: 18723476
[TBL] [Abstract][Full Text] [Related]
2. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.
Vosjan MJ; Perk LR; Roovers RC; Visser GW; Stigter-van Walsum M; van Bergen En Henegouwen PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):753-63. PubMed ID: 21210114
[TBL] [Abstract][Full Text] [Related]
3. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20.
Krasniqi A; Bialkowska M; Xavier C; Van der Jeught K; Muyldermans S; Devoogdt N; D'Huyvetter M
N Biotechnol; 2018 Oct; 45():69-79. PubMed ID: 29574274
[TBL] [Abstract][Full Text] [Related]
5. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
6. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
8. Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab
Jureczek J; Feldmann A; Bergmann R; Arndt C; Berndt N; Koristka S; Loureiro LR; Mitwasi N; Hoffmann A; Kegler A; Bartsch T; Bachmann M
Onco Targets Ther; 2020; 13():5515-5527. PubMed ID: 32606767
[TBL] [Abstract][Full Text] [Related]
9. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
[TBL] [Abstract][Full Text] [Related]
10. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
[TBL] [Abstract][Full Text] [Related]
12. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
13. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
[TBL] [Abstract][Full Text] [Related]
14. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
Vosjan MJ; Vercammen J; Kolkman JA; Stigter-van Walsum M; Revets H; van Dongen GA
Mol Cancer Ther; 2012 Apr; 11(4):1017-25. PubMed ID: 22319202
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
[TBL] [Abstract][Full Text] [Related]
16. Functional production of a soluble and secreted single-chain antibody by a bacterial secretion system.
Cheng CM; Tzou SC; Zhuang YH; Huang CC; Kao CH; Liao KW; Cheng TC; Chuang CH; Hsieh YC; Tai MH; Cheng TL
PLoS One; 2014; 9(5):e97367. PubMed ID: 24824752
[TBL] [Abstract][Full Text] [Related]
17. Cumulated Activity Comparison of
Laffon E; Thumerel M; Jougon J; Marthan R
J Nucl Med; 2017 Jun; 58(6):888-890. PubMed ID: 28082435
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor.
Niu G; Cai W; Chen K; Chen X
Mol Imaging Biol; 2008; 10(2):99-106. PubMed ID: 18157579
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.
Milenic DE; Wong KJ; Baidoo KE; Ray GL; Garmestani K; Williams M; Brechbiel MW
Cancer Biother Radiopharm; 2008 Oct; 23(5):619-31. PubMed ID: 18999934
[TBL] [Abstract][Full Text] [Related]
20. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
